

LUD 5483.7 DIV (10316191)

IN THE SPECIFICATION

Page 1, please amend the first paragraph as follows:

This is a divisional of Serial No: 09/789,649 filed February 21, 2001, which is a divisional of Serial No. 09/099,543 filed June 18, 1998, now U.S. Patent 6,326,200, which is a continuation-in-part of Serial No. 09/061,388, filed April 16, 1998, now U.S. Patent 6,277,956, which is a continuation in part of Serial No. 08/880,963, filed June 23, 1997, now U.S. Patent ~~6,052,470~~ 6,025,470, all of which are incorporated by reference. A portion of the invention was published by the inventors, less than one year before the filing date of the first continuation-in-part application. See Romero et al., J. Immunol. 159: 2366 (1997) incorporated by reference.

Page 7, line 8, please amend as follows:

Figures 2a-2d show stability studies comparing various peptides (SEQ ID NOS: 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17).

Page 7, lines 10-20, please amend as follows:

Figure 4 parallels figure 3, but uses CTLs generated from PBLs by stimulation of PBMCs with various peptides (SEQ ID NOS: 1, 2, 9).

Figures 5a-5r show results of flow cytometry studies, following stimulation of PBMCs with various peptides (SEQ ID NOS. 1, 2, 9, 15, 16, 17).

Figures 6a-6e depict results of lytic activity assays on PBMCs which have been stimulated with various peptides (SEQ ID NOS: 1, 2, 9, 15, 16).

Figures 7a-7e present data on Melan-A specific lytic activity of fluorescently sorted lymphocytes positive for tetramers containing SEQ ID NO: 1, following stimulation with other peptides (SEQ ID NOS.1, 2, 9, 15, 16).

Figure 8 shows quantitative assessment of peptide dependent lytic activity of Melan-A monospecific CTL line. (SEQ ID NO: 1, 2, 9, 15, 16).

Page 10, lines 6-10, please replace with the following:

LUD 5483.7 DIV (10316191)

AAGIGILTV ₂₇₋₃₅ (SEQ ID NO: 2)	40	1	15	1
EAAGIGILTV ₂₆₋₃₅ (SEQ ID NO: 1)	1.5	27	1	15
AAGIGILTVI ₂₇₋₃₆ (SEQ ID NO: 3)	600	0.06	300	0.05
ILTVILGV ₃₂₋₄₀ (SEQ ID NO: 4)	>10 ⁴	<4 x 10 ⁻³	>10 ⁴	<1.5 x 10 ⁻³

Please replace page 12 with the attached page 12.

Please replace page 14 with the attached page 14.

Please replace page 15 with the attached page 15.

Please replace page 17, with the attached page 17.

Page 28, lines 26-29, please amend as follows:

The peptides may be combined with peptides from other tumor rejection antigens to form 'polytopes'. Exemplary peptides include those listed in U.S. Patent Application Serial Numbers 08/672,351, 08/718,964, now ~~U.S. Patent No. _____~~ abandoned, 08/487,135, now U.S. Patent No. 5,821,122, 08/530,569 and 08/880,963 all of which are incorporated by reference.